NCT06058234 · RECRUITING
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
This is not a typical drug experiment. It is a Medicare-required data collection study tracking real-world outcomes for patients already receiving FDA-approved anti-amyloid antibody drugs such as lecanemab or donanemab. Medicare mandated this registry as a condition of coverage. Researchers are gathering clinical and claims data to see how these drugs perform outside of controlled trials. No phase applies because no experimental treatment is being tested here.
You may qualify if
- Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.
You're excluded if
- none
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2023-09-28